From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
Subgroup | Standard care | Ivabradine + Standard care | Incremental costs & outcomes | ||||||
---|---|---|---|---|---|---|---|---|---|
Total costs (in €) | Total QALYs | Total costs (in €) | Total QALYs | Costs (in €) | LYs | QALYs | Cost/LY (in €) | Cost/QALY (in €) | |
All patients (HR ≥ 75 b.p.m.) | 5,873 | 3.99 | 8,665 | 4.27 | 2,792 | 0.25 | 0.28 | 11,002 | 9,986 |
Age < 75 years | 6,033 | 4.14 | 8,932 | 4.43 | 2,899 | 0.27 | 0.29 | 10,897 | 9,909 |
Age ≥ 75 years | 4,350 | 2.54 | 6,123 | 2.69 | 1,772 | 0.14 | 0.16 | 12,944 | 11,355 |
NYHA II | 6,358 | 4.55 | 9,498 | 4.84 | 3,140 | 0.24 | 0.28 | 12,935 | 11,112 |
NYHA III | 5,528 | 3.55 | 8,059 | 3.83 | 2,531 | 0.27 | 0.28 | 9,542 | 9,044 |
NYHA IV | 3,383 | 1.79 | 4,726 | 2.00 | 1,343 | 0.22 | 0.21 | 6,018 | 6,445 |
HF duration <0.6 years | 6,683 | 5.02 | 10,063 | 5.35 | 3,379 | 0.28 | 0.33 | 12,085 | 10,287 |
HF duration ≥0.6 < 2 years | 5,881 | 4.10 | 8,752 | 4.39 | 2,871 | 0.26 | 0.29 | 10,919 | 9,883 |
HF duration ≥2 < 4.8 years | 5,489 | 3.66 | 8,138 | 3.92 | 2,648 | 0.24 | 0.26 | 10,916 | 10,168 |
HF duration ≥4.8 years | 5,466 | 3.20 | 7,755 | 3.44 | 2,290 | 0.23 | 0.24 | 9,931 | 9,527 |
No beta blocker | 5,144 | 3.08 | 7,384 | 3.39 | 2,240 | 0.31 | 0.31 | 7,239 | 7,267 |
Beta blocker < half target dose | 5,481 | 3.60 | 7,992 | 3.87 | 2,511 | 0.25 | 0.27 | 9,942 | 9,250 |
Beta blocker = > half target dose < target dose | 6,338 | 4.45 | 9,438 | 4.73 | 3,100 | 0.24 | 0.28 | 12,794 | 11,115 |
Beta blocker = > target dose | 6,440 | 4.64 | 9,684 | 4.92 | 3,244 | 0.24 | 0.28 | 13,602 | 11,619 |
LVEF < 26% | 5,407 | 3.31 | 7,709 | 3.60 | 2,302 | 0.28 | 0.29 | 8,356 | 8,072 |
LVEF ≥26% < 30% | 5,483 | 3.66 | 8,052 | 3.94 | 2,569 | 0.25 | 0.27 | 10,163 | 9,440 |
LVEF ≥30 < 33% | 5,993 | 4.19 | 8,947 | 4.47 | 2,955 | 0.26 | 0.28 | 11,558 | 10,400 |
LVEF ≥ 33% | 6,443 | 4.64 | 9,688 | 4.92 | 3,245 | 0.23 | 0.27 | 13,977 | 11,807 |
Non-diabetic | 5,746 | 4.04 | 8,577 | 4.32 | 2,831 | 0.25 | 0.28 | 11,210 | 10,112 |
Diabetic | 6,150 | 3.86 | 8,859 | 4.14 | 2,709 | 0.26 | 0.28 | 10,556 | 9,710 |
No prior CAD | 5,839 | 4.20 | 8,719 | 4.52 | 2,880 | 0.29 | 0.32 | 9,907 | 9,051 |
Prior CAD | 5,887 | 3.90 | 8,643 | 4.16 | 2,756 | 0.24 | 0.26 | 11,549 | 10,448 |